Search research articles
Contact Us
Filters
Showing results (61-70 of 246) with videos related to
Page
of 25
Sort By:
Hepatology (Baltimore, Md.)
|
December 24, 2016
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention
Giovanni Brandi, Stefania De Lorenzo, Andrea Palloni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2004
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease
Guido Biasco, Maria Abbondanza Pantaleo, Giulio Di Febo, et al.
Expert Review of Gastroenterology & Hepatology
|
November 15, 2024
Advances in target drugs and immunotherapy for biliary tract cancer
Chiara Deiana, Chiara Ricci, Mahrou Vahabi, et al.
Cutaneous and Ocular Toxicology
|
May 4, 2013
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
Annalisa Patrizi, Michela Venturi, Emi Dika, et al.
Seminars in Cancer Biology
|
September 18, 2021
Microbiota and prostate cancer
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, et al.
Cutaneous and Ocular Toxicology
|
March 29, 2013
Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
Giovanni Brandi, Michela Venturi, Emi Dika, et al.
Expert Review of Gastroenterology & Hepatology
|
March 31, 2021
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, et al.
Annals of Global Health
|
June 27, 2022
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
Giovanni Brandi, Kurt Straif, Daniele Mandrioli, et al.
European Urology
|
July 29, 2008
Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
Giovanni Brandi, Francesco de Rosa, Romano Danesi, et al.
Nature Reviews. Clinical Oncology
|
February 29, 2024
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Page
of 25
Search research articles
Search
Showing results (61-70 of 246) with videos related to
Sort By:
Page
of 25
Hepatology (Baltimore, Md.)
|
December 24, 2016
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention
Giovanni Brandi, Stefania De Lorenzo, Andrea Palloni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2004
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease
Guido Biasco, Maria Abbondanza Pantaleo, Giulio Di Febo, et al.
Expert Review of Gastroenterology & Hepatology
|
November 15, 2024
Advances in target drugs and immunotherapy for biliary tract cancer
Chiara Deiana, Chiara Ricci, Mahrou Vahabi, et al.
Cutaneous and Ocular Toxicology
|
May 4, 2013
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
Annalisa Patrizi, Michela Venturi, Emi Dika, et al.
Seminars in Cancer Biology
|
September 18, 2021
Microbiota and prostate cancer
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, et al.
Cutaneous and Ocular Toxicology
|
March 29, 2013
Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
Giovanni Brandi, Michela Venturi, Emi Dika, et al.
Expert Review of Gastroenterology & Hepatology
|
March 31, 2021
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, et al.
Annals of Global Health
|
June 27, 2022
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
Giovanni Brandi, Kurt Straif, Daniele Mandrioli, et al.
European Urology
|
July 29, 2008
Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
Giovanni Brandi, Francesco de Rosa, Romano Danesi, et al.
Nature Reviews. Clinical Oncology
|
February 29, 2024
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Page
of 25